PMID- 22913983
OWN - NLM
STAT- MEDLINE
DCOM- 20130617
LR  - 20151119
IS  - 1523-1755 (Electronic)
IS  - 0085-2538 (Linking)
VI  - 83
IP  - 1
DP  - 2013 Jan
TI  - Circulating complement activation in patients with anti-neutrophil cytoplasmic 
      antibody-associated vasculitis.
PG  - 129-37
LID - 10.1038/ki.2012.313 [doi]
AB  - Studies in animal models suggest that complement activation is crucial in the 
      pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). 
      Here we investigate the circulating complement activation profile of 66 patients 
      with active stage AAV compared to that of 54 patients with AAV in remission. 
      Plasma levels of C3a, C5a, soluble C5b-9, and Bb, all determined by enzyme-linked 
      immunosorbent assay, were significantly higher in active stage than in remission 
      of AAV, while plasma levels of properdin were significantly lower in the former 
      than the latter disease stage. There was no significant difference in the plasma 
      levels of C4d between active stage and remission. The plasma level of Bb in 
      patients with active AAV significantly correlated with the proportion of total 
      and cellular crescents in the renal biopsy, the erythrocyte sedimentation rate, 
      and the Birmingham Vasculitis Activity Scores. Thus, systemic activation of 
      complement by the alternative pathway takes place in human AAV. Circulating Bb 
      might be a useful biomarker in assessing disease activity of AAV.
FAU - Gou, Shen-Ju
AU  - Gou SJ
AD  - Renal Division, Department of Medicine, Peking University First Hospital, 
      Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, 
      Ministry of Health of China, Key Laboratory of CKD Prevention and Treatment, 
      Ministry of Education of China, Beijing, China.
FAU - Yuan, Jun
AU  - Yuan J
FAU - Chen, Min
AU  - Chen M
FAU - Yu, Feng
AU  - Yu F
FAU - Zhao, Ming-Hui
AU  - Zhao MH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120822
PL  - United States
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
RN  - 0 (Biomarkers)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Peptide Fragments)
RN  - 80295-42-7 (Complement C3a)
RN  - 80295-50-7 (Complement C4b)
RN  - 80295-52-9 (complement C4d)
RN  - 80295-54-1 (Complement C5a)
RN  - 80295-55-2 (Complement C5b)
RN  - EC 3.4.21.47 (Complement Factor B)
SB  - IM
CIN - Kidney Int. 2013 Jan;83(1):16-8. PMID: 23271485
CIN - Kidney Int. 2013 Nov;84(5):1048-9. PMID: 24172736
CIN - Kidney Int. 2013 Nov;84(5):1048. PMID: 24172737
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*blood/*diagnosis/drug 
      therapy
MH  - Biomarkers/blood
MH  - *Complement Activation
MH  - Complement C3a/metabolism
MH  - Complement C4b/metabolism
MH  - Complement C5a/metabolism
MH  - Complement C5b/metabolism
MH  - Complement Factor B/*metabolism
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/metabolism
MH  - Remission Induction
MH  - *Severity of Illness Index
MH  - Young Adult
EDAT- 2012/08/24 06:00
MHDA- 2013/06/19 06:00
CRDT- 2012/08/24 06:00
PHST- 2012/08/24 06:00 [entrez]
PHST- 2012/08/24 06:00 [pubmed]
PHST- 2013/06/19 06:00 [medline]
AID - S0085-2538(15)55692-5 [pii]
AID - 10.1038/ki.2012.313 [doi]
PST - ppublish
SO  - Kidney Int. 2013 Jan;83(1):129-37. doi: 10.1038/ki.2012.313. Epub 2012 Aug 22.